Dr. Ann De Wees Allen

  "Dr. Allen is known in the industry as the "Alpha Scientist".  Dr. Allen is in the forefront of scientific breakthroughs, including the Glycemic Index, Brain Glycemic Index, Cephalic Response, Adipose Tissue Fat Storage, Fat Cell Key Codes, Obesity, Diabetes, Childhood Obesity, Low Glycemic Food Development, Low Glycemic Glycoside Sweeteners, L-Arginine, Blind Amino Acid, Riders, L-Arginine Isofrom Pathways, Sick Cell & Thalassemia; Genetic Polymorphisms in Dysregulated Arginine Metabolism, Edible Computer Chips, Soft Particle Nanotechnology, Human Maximum Performance in Athletes, Non-fattening, diabetic-friendly chocolate candy and ice cream.

   For the past 25 years, Dr. Allen has been a world leader in Glycemic Index and L-Arginine research.  Her vast portfolio of patents has revolutionized the food, Nutraceutical, and Pharmaceutical industries and has been featured on the front page of the Wall Street Journal.  Dr. Allen's patent licensing has generated over a billion dollars and continues to break all global records in licensing-technology, including Breakthrough Product of the Year by Success magazine.

   Dr. Allen was awarded the first Glycemic Patent, the first l-Arginine Patent, the first Sickle Cell Patent, and is credited with the discovery that L-Arginine is a Blind Amino Acid, which led to her discoveries on the mechanism for formulating safe L-Arginine.

   As Chief of Biomedical Research at the Glycemic Research Institute in Washington D.C., Dr. Allen has made more discoveries in glycemic food technology than any other scientist worldwide.  The Glycemic Research Institute is the only Glycemic government Certification trial laboratory in the United States, and is also authorized by the United Kingdom and Canadian Governments."

Dr. Ann de Wees Allen
Chief of Boresha's Medical Board